Abstract
Cancer is a multifactorial disease including interactions of complex genetic and environmental factors. Clinical efficacy of anticancer chemotherapies is hampered by various factors including multidrug resistance (MDR). There is a strong need to discover more potent novel cancer drugs to kill cancer cells selectively. The recent new strategy for cancer treatment involves the design and synthesis of hybrid compounds as multitargeted anticancer agents. In this review, we focus on studies using hybrid compounds which were designed and synthesized from two or more different bioactive moieties conjugating them into a single hybrid drug. Hybrid compounds having more than a single target have been considered as more efficient and potent anticancer agents, since it is almost impossible to destroy cancer cells with a single target. Hybrid compounds overcome many disadvantages of single cancer drugs such as low solubility, adverse effects, and multi drug resistance. We have compiled the data of recent studies using the new hybrid anticancer drugs in cancer treatment. Thus, the design, synthesis and clinical trials of new hybrid compounds should be continued and supported in future. Results of recent studies have proved that they have a great potential to be used as novel anticancer drugs.
Keywords: Hybrid Compounds, Cancer, Anticancer Agents, Multitarget Compounds, Drug Design, Natural Products.
Current Topics in Medicinal Chemistry
Title:Hybrid Compounds as Multitarget Directed Anticancer Agents
Volume: 17 Issue: 8
Author(s): Ertan Kucuksayan and Tomris Ozben
Affiliation:
Keywords: Hybrid Compounds, Cancer, Anticancer Agents, Multitarget Compounds, Drug Design, Natural Products.
Abstract: Cancer is a multifactorial disease including interactions of complex genetic and environmental factors. Clinical efficacy of anticancer chemotherapies is hampered by various factors including multidrug resistance (MDR). There is a strong need to discover more potent novel cancer drugs to kill cancer cells selectively. The recent new strategy for cancer treatment involves the design and synthesis of hybrid compounds as multitargeted anticancer agents. In this review, we focus on studies using hybrid compounds which were designed and synthesized from two or more different bioactive moieties conjugating them into a single hybrid drug. Hybrid compounds having more than a single target have been considered as more efficient and potent anticancer agents, since it is almost impossible to destroy cancer cells with a single target. Hybrid compounds overcome many disadvantages of single cancer drugs such as low solubility, adverse effects, and multi drug resistance. We have compiled the data of recent studies using the new hybrid anticancer drugs in cancer treatment. Thus, the design, synthesis and clinical trials of new hybrid compounds should be continued and supported in future. Results of recent studies have proved that they have a great potential to be used as novel anticancer drugs.
Export Options
About this article
Cite this article as:
Kucuksayan Ertan and Ozben Tomris, Hybrid Compounds as Multitarget Directed Anticancer Agents, Current Topics in Medicinal Chemistry 2017; 17 (8) . https://dx.doi.org/10.2174/1568026616666160927155515
DOI https://dx.doi.org/10.2174/1568026616666160927155515 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options
Current Cancer Therapy Reviews MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Synthesis and Antitumor Invasive Activity of Novel Ionone Alkaloid Derivatives
Letters in Drug Design & Discovery Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry In Vivo Biological Evaluation of Ethyl 4-(7-hydroxy-4-methyl-2-oxoquinolin-1- ylamino)-coumarin-3-carboxylate as an Antitumor Agent
Anti-Cancer Agents in Medicinal Chemistry Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer
Current Cancer Drug Targets Perturbation of HSP Network in MCF-7 Breast Cancer Cell Line Triggers Inducible HSP70 Expression and Leads to Tumor Suppression
Anti-Cancer Agents in Medicinal Chemistry Role of α7-Nicotinic Acetylcholine Receptor in Normal and Cancer Stem Cells
Current Drug Targets Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry Design of Novel Antitumor DNA Alkylating Agents: The Benzacronycine Series
Current Medicinal Chemistry - Anti-Cancer Agents Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Parallel Solid-Phase Synthesis using a New Diethylsilylacetylenic Linker and Leading to Mestranol Derivatives with Potent Antiproliferative Activities on Multiple Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Peripherally Located A431 Cells are More Sensitive to Cell Death Induced by Exogenous Oxidative Stress
Current Signal Transduction Therapy Editorial: (Thematic Issue Cancer Immunotherapy: Does an Increasing Arsenal of Tools Point to More Fruitful Avenues for Research?)
Anti-Cancer Agents in Medicinal Chemistry Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals